Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer

In brief

This phase II trial studies how well androgen deprivation therapy and vorinostat followed by radical prostatectomy works in treating patients with prostate cancer that has not spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, goserelin acetate, and leuprolide acetate, may lessen the amount of androgens made by the body. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving androgen deprivation therapy and vorinostat before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Key facts

Study ID

NCT00589472

Run by

National Cancer Institute (NCI)

People needed

19

Starts

2007-11-01

Expected to finish

2010-06-01

Last updated by the study team

2017-10-06

Who can join

Age: 19 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologic documentation of prostatic adenocarcinoma in 3 or more biopsy cores, of which at least 1 core demonstrates > 30% involvement with tumor; confirmation of localized disease by magnetic resonance imaging (MRI) with endorectal probe if available
• No evidence of distant disease on a:
• Computed tomography (CT) or MRI of the abdomen and pelvis
• Radionuclide bone scan (with plain film or MRI confirmation as clinically indicated)
• Appropriate candidate for radical prostatectomy
• Adequate cardiac function (evidence of cardiac disease should be evaluated to determine appropriateness of patient as a surgical candidate)
• Candidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic anticoagulation, if otherwise deemed to be suitable for radical prostatectomy
• White blood cell (WBC) > 3000/uL
• Platelets > 150,000/uL
• Creatinine < 2 mg/dL
• Serum PSA < 100 ng/mL
• Bilirubin < 1.5 X ULN (institutional upper limits of normal)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2 X ULN
• Karnofsky performance status > 70%
• Willingness to undergo pretreatment transrectal ultrasound-guided prostate needle biopsy (optional)
• Willingness to use adequate contraceptive methods during study therapy and for at least 3 months after completion of therapy
• Ability to understand and willingness to sign a written informed consent document

You may not qualify if…

• Evidence of small-cell, transitional-cell, or neuroendocrine pathologic features
• Prior hormonal therapy with (e.g. 5-alpha-reductase inhibitors, gonadotropin hormone releasing analogs, steroids, megestrol acetate, or nonstudy-related antiandrogens), chemotherapy, or herbal medications administered with the intent to treat the patient's malignancy
• Patients on valproic acid (a histone-deacetylase inhibitor) to treat prostate cancer are not eligible
• History of allergic reactions attributed to compounds of similar chemical or biological composition to vorinostat
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would compromise compliance with study requirements
• Currently active secondary malignancy (as determined by the treating physician) other than non-melanoma skin cancer

Where it is running

• UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States
• UCSF Medical Center-Parnassus — San Francisco, California, United States
• University of Chicago Comprehensive Cancer Center — Chicago, Illinois, United States
• Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Wayne State University/Karmanos Cancer Institute — Detroit, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• UMDNJ - New Jersey Medical School — Newark, New Jersey, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Oregon Health and Science University — Portland, Oregon, United States
• M D Anderson Cancer Center — Houston, Texas, United States
• University of Washington Medical Center — Seattle, Washington, United States
• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.